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tion, all with p<0.01. In CHB patients, MIF, TGF-, IL-17 and ALT
levels were positively correlated (r = 0.725, 0.687, 0.831; p<0.01,
0.05, 0.01, respectively), IL-10 and ALT was negatively correlated
(r = -0.562, p =<0.05). .Multivariate analysis showed that the lev-
els of increment of MIF, TGF- and IL-17 were associated with the
increment of HBV DNA load and severity of liver disease.
Conclusion: There is amarked correlation between the concen-
tration of MIF, TGF- and IL-17 and the severity of liver disease
and viral replication. Increased serum levels of MIF, TGF- and IL-
17 correlate positively with the severity of liver disease and active
viral replication in chronic HBV infection.
http://dx.doi.org/10.1016/j.ijid.2014.03.1081
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Background: Chronic hepatitis B is a serious health problem
worldwide with a substantial minority of patients experiencing
premature death due to end-stage liver disease and/or hepatocel-
luar carcinoma. Antiviral therapy may help prevent complications
of chronic hepatitis B, and seven agents are currently approved
in many countries. Of these agents, ﬁve are nucleos(t)ide analogs
that all have a risk of antiviral drug resistance with long-term
use. Entecavir treatment has signiﬁcantly improved the outcome
of chronic hepatitis B virus (HBV) infection and with a lowest resis-
tance risk. However, it remains largely unknown how immune
systemresponds to the treatment. The aimof thepresent study is to
investigate dynamic ﬂuctuations of serum viral load and Th1/Th2
immunity of chronic hepatitis B patients and their correlation dur-
ing long-term entecavir therapy.
Methods & Materials: Sixty-two patients received entecavir
0.5mg/d therapy. Serum HBVDNA load was measured by Real-
Time-PCR, and the levels of cytokines and T helper 1 (Th1) and
2 (Th2) cytokine producing T-cells by ﬂow cytometry during 260
weeks of the treatment. Multilevel modelling was used to analyse
the relationship between these variables.
Results: Of the 62 patients, all HBeAg positive and with
detectable HBVDNA, the majority (85.6%) had serum levels of
HBVDNA over 107 copies per milliliter. Th1/Th2 cytokines produc-
ingT-cellswere signiﬁcantly lower in chronichepatitis Bpatients as
comparedwith normal individuals. HBV viral load dropped sharply
during the ﬁrst two weeks. In 31 and 48 patients, the level became
undetectable fromweek 24 and 48, respectively. Using pre-therapy
level as the reference, a signiﬁcant increase in Th1/Th2 cytokines
producing T-cells and serum cytokine levels were found from
week 12. These parameters and Th1/Th2 balance steadlly improved
throughout the 260 weeks. Multilevel analyses showed that the
level of decrement of HBVDNA load was associated with the incre-
ment of Th1/Th2 activities only in the later period (12-260 week).
In contrast, Th1/Th2 cytokines producing T-cells remained lower in
one patient detected with entecavir resistant HBV mutation.
Conclusion: Decline of HBVDNA load correlate with increase of
Th1/Th2 immunity in chronic hepatitis B patients during a long-
term treatment with entecavir.
http://dx.doi.org/10.1016/j.ijid.2014.03.1082
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Background:Hepatitis B virus (HBV) andhepatitis C virus (HCV)
infections are among themost common causes of advanced chronic
liver disease worldwide. HBV/HCV co-infection is not uncommon
and the patients with HBV/HCV co-infection have an increased risk
of cirrhosis, hepatocellular carcinoma (HCC), and even death. The
combination of pegylated interferon (Peg-IFN) plus ribavirin (RBV)
is the current standard of care for naïve chronic hepatitis C patients,
achieving a high sustained virological response (SVR) rate. The aim
ofpresent study is toexplore the clinical characteristics ofHBV/HCV
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co-infected patients and the impact of co-infection on the efﬁcacy
of Peg-IFN/RBV combination therapy.
Methods & Materials: The clinical characteristics of HBV/HCV
co-infected patients and the virological responses to Peg-IFN/RBV
combination therapy in 89 HBV and HCV co-infected patients were
retrospectively analyzed. The primary outcome measurement of
antiviral treatment was SVR (seronegative of HCVRNA throughout
the 6-month post-treatment follow-up period).
Results: Of the 89 HBV/HCV co-infected patients, HCV strains
were dominant in 76 patients (85.4%), while HCV and HBV strains
were both dominant 13 patients (14.6%). HBV DNA load level and
HBeAg positive rate in HBV/HCV co-infected patients was signiﬁ-
cantly lower than that inHBVmono-infected group (p<0.01, 0.001,
respectively). Serum levels of ALT and AST in co-infected patients
were obviously higher than that inmono-infected group (p<0.001,
0.001, respectively). The SVR rate was signiﬁcantly lower in the
HBV/HCVco-infectedpatients compared to theHCVmono-infected
patients (p <0.05). However, the signiﬁcantly lower rate of SVR in
the co-infected group was observed among genotype-1 patients
(p <0.05) but not among genotype-2/3 patients (p >0.05). Partial
early virological response (pEVR) rates and virological response
at the end of treatment (ETVR) rates were signiﬁcantly higher in
patients co-infected with genotype 1 of HCV and HBV than those in
HCVmono-infectedpatients (p <0.01, 0.01, respectively). Nodiffer-
ences in rapidvirological response (RVR), completeearlyvirological
response (cEVR), and relapse were observed between co-infected
patients with non-genotype 1 of HCV and HBV and mono-infected
patients with non-genotype 1 of HCV.
Conclusion: Co-infection with HBV and non-genotype 1 of HCV
hasno impact onvirological responses toPeg-IFN/RBVcombination
therapy.
http://dx.doi.org/10.1016/j.ijid.2014.03.1083
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Background: Winter inﬂuenza planning is a part of health ser-
vices’ preparation for the annual increase in hospital admissions
due to respiratory virus infections in New Zealand. The diagnos-
tic virology service for Canterbury District Health Board’s hospitals
extended respiratory pathogen testing in 2012 using a multiplex
PCR test.
This study is an audit over 2 years of the outcomes of patients
requiring ICU admission for respiratory support, with either
inﬂuenza or another respiratory virus diagnosis.
Methods & Materials: Respiratory samples were tested using
the Fast-track Diagnostics (FTD) respiratory pathogen multiplex
PCR for the detection of 19 viruses.
The Laboratory Information System was searched for records of
all admitted patientswith a PCR respiratory virus diagnosis in 2012
and2013. Adult patients, 18 years andover requiring IntensiveCare
Unit respiratory support, were included.
The hospital electronic database was searched for patient
admission diagnosis, chronic illness, length of admission, antibiotic
prescribing and mortality related to the ICU admission.
Results:A total of 782 patients admitted to hospital had a respi-
ratory virus diagnosis. Of 312 adult patients with inﬂuenza, 15
required ICU support, ofwhomtwodied (13.3%),while, of 470 adult
patients with another respiratory virus, 35 required ICU support of
whom 10 died (28.6%).
Themost common admitting diagnosiswas “acute exacerbation
COPD” and “Pneumonia”, comprising 4 and 5 respectively for the
Inﬂuenza group, and 12 and 13 in the other virus group.
The most common premorbid condition was COPD, including 5
(33%) of the inﬂuenza group and 15 (43%) of the other virus group.
Length of stay for patients in the Inﬂuenza group was median 5
days (1-30 days) and other virus group median 5 days (1-24 days).
All but nine ICU patients received one or more antibiotics dur-
ing admission and eight of 15 patients with inﬂuenza received
Oseltamivir.
Conclusion: Adult patients with viral respiratory infections
other than inﬂuenza and requiring ICU admission have similar
length of stay, but increased mortality, as those with inﬂuenza in
ICU,. COPD is an important premorbid condition for severe out-
comes for all respiratoryvirus infections.Winter inﬂuenzaplanning
should include the planning for admission of patients with non-
inﬂuenza respiratory viruses.
http://dx.doi.org/10.1016/j.ijid.2014.03.1084
